Table 2.
Dinaciclib-related non-hematologic adverse events occurring in ≥2 (10 %) patients
| Adverse events | Cycle 1 n = 20 |
Cycle 2 n = 10 |
Cycle 3 n = 6 |
|||
|---|---|---|---|---|---|---|
| All (%) | Grade ≥3 | All (%) | Grade ≥3 | All (%) | Grade ≥3 | |
| Cardiovascular | ||||||
| Hypertension | 1 (5) | − | − | − | 1 (17) | − |
| Hypotension | 6 (30) | 1 | 2 (20) | − | − | − |
| Sinus Tachycardia | 2 (10) | − | − | − | − | − |
| Constitutional | ||||||
| Cytokine release sy | 2 (10) | − | − | − | 1 (17) | 1 |
| Dehydration | 1 (5) | 1 | 1 (10) | − | − | − |
| Fatigue | 6 (30) | 2 | 2 (20) | 1 | 1 (17) | 1 |
| Gastrointestinal | ||||||
| Anorexia | 1 (5) | − | − | − | 1 (17) | − |
| Diarrhea | 14 (70) | 1 | 7 (70) | 1 | 2 (33) | − |
| Nausea | 8 (40) | 1 | 3 (30) | − | 1 (17) | − |
| Stomatitis | 1 (5) | − | 1 (10) | 1 | − | − |
| Vomiting | 9 (45) | − | 2 (20) | − | 2 (33) | − |
| Hepatic | ||||||
| Hyperbilirubinemia | 2 (10) | − | 1 (10) | − | − | − |
| Increased ALT | 4 (20) | − | 1 (10) | − | 1 (17) | − |
| Increased AST | 8 (40) | 3 | 1 (10) | − | − | − |
| Infections | ||||||
| Bacteremia | 2 (10) | 2 | − | − | − | − |
| Pneumonia | 2 (10) | 2 | 1 (10) | − | − | − |
| Metabolic and electrolyte abnormalities | ||||||
| Hyperglycemia | 4 (20) | 2 | − | − | − | − |
| Hyperkalemia | 3 (15) | 2 | 1 (10) | − | − | − |
| Hyperphosphatemia | 5 (25) | 1 | 1 (10) | − | − | − |
| Hypoalbuminemia | 4 (20) | − | 1 (10) | − | − | − |
| Hypocalcemia | 6 (30) | 1 | − | − | − | − |
| Hypokalemia | 2 (10) | − | − | − | − | − |
| Hyponatremia | 2 (10) | 1 | − | − | − | − |
| Increased LDH | 2 (10) | 2 | − | − | − | − |
| Tumor lysis sy | 3 (15) | 3 | − | − | − | − |
| Neurology | ||||||
| Syncope | 1 (5) | 1 | 1 (10) | 1 | − | − |
| Renal | ||||||
| Acute renal failure | 2 (10) | 2 | − | − | − | − |
| Increased creatinine | 3 (15) | 1 | − | − | − | − |